Radafaxine
From Wikipedia, the free encyclopedia
![]() |
|
|
Radafaxine
|
|
| Systematic (IUPAC) name | |
| (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C13H18ClNO2 |
| Mol. mass | 255.74 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Radafaxine is a drug currently in development by GlaxoSmithKline. GlaxoSmithKline is targeting Radafaxine for regulatory filing in 2007.[1]
It is a potent metabolite of bupropion, the compound in GlaxoSmithKline's Wellbutrin. More specifically, "hydroxybupropion" is a hydroxy derivative of bupropion, and radafaxine is an isolated isomer of hydroxybupropion.[2]
Therefore, radafaxine builds on at least some of the properties of bupropion in humans.[3]
Presently in various clinical trials, radafaxine is being studied as a treatment for clinical depression, obesity, and neuropathic pain. Radafaxine is described as a norepinephrine-dopamine reuptake inhibitor (NDRI).
Unlike bupropion (which has a slightly higher effect on dopamine reuptake), radafaxine seems to have a higher potency on norepinephrine. This, according to GlaxoSmithKline, may account for the increased effect of radafaxine on pain and fatigue.[4]
At least one study suggests that radafaxine has a low abuse potential similar to bupropion.[5]
